Clinical Development
Hyperion Therapeutics is a specialty therapeutics company dedicated to improving patients’ lives through the development of therapeutic programs and products that address underserved patient populations or unmet medical needs. The Company is focused on gastrointestinal (GI) and hepatology related diseases.
Product Development Pipeline
 |
|||||||||||
|
|||||||||||
Further information on trials currently enrolling is available via the following links: hepatic encephalopathy and urea cycle disorder or by calling 866-563-9572.
About Urea Cycle Disorders
A urea cycle disorder (UCD) is an inherited, inborn error of metabolism. Patients with a UCD lack or are deficient in one of the key enzymes that comprise the urea cycle, the body’s primary vehicle for removing ammonia, a potent neurotoxin, from the bloodstream. Left untreated, UCDs can cause dangerously heightened levels of ammonia in the bloodstream (hyperammonemia) resulting in brain damage, coma, and/or death.
Additional information on urea cycle disorders is available from The National Urea Cycle Disorders Foundation (NUCDF), a nonprofit organization dedicated to the identification, treatment and cure of urea cycle disorders, and The Urea Cycle Disorders Consortium (UCDC) of the Rare Diseases Clinical Research Network, a National Institutes of Health (NIH)-funded research initiative.
About Hepatic Encephalopathy
Hepatic encephalopathy (HE) results from a complication of liver failure. Patients with HE experience an accumulation of toxic substances in the bloodstream typically removed by the liver, impairing the function of brain cells to the point of coma or death in severe cases.
AMMONUL is a registered trademark of Ucyclyd Pharma, Inc.
© 2008 Ucyclyd Pharma, Inc.